Belviq

The Food and Drug Administration approved the weight loss drug Belviq in the United States in 2012. This approval was given with the condition that the manufacturer, Eisai, conduct clinical trials to determine the extent of any cardiovascular risks. Following this study, it was determined in 2018 that there was no relation to heart problems, they found a startling link to higher cancer diagnosis in patients taking Belviq versus those taking the placebo. The FDA requested that Eisai voluntarily recall Belviq in February 2020 and they complied.

Belviq was designed to help with weight-loss for obese people with at least one weight related health condition, such as high blood pressure or diabetes. These people often had a hard time with diet, exercise, and other lifestyle adjustments alone. Serotonin is a hormone that provides us with happy and positive feelings, stabilizes our mood, and aids with sleep and digestion. Belviq targeted the Serotonin receptors that controlled appetite and once activated, people had a feeling of satisfaction and being full.

The FDA initially declined to approve Belviq in 2010 as there was evidence that it caused tumors in rodents during clinical testing. Following additional modifications, the approval was granted, and Eisai advised the FDA that there was no greater risk to their patients as those who took a placebo. This was clearly not the case.

The following cancers are most frequently linked to the use of Belviq:

• colorectal cancer
• lung cancer
• pancreatic cancer
• others, such as breast cancer and brain cancer, are currently being evaluated

Due to the increasing concern for developing cancers over time, the FDA recommended that patients stop taking Belviq in February 2020 and that doctors stop prescribing Belviq.

A drug manufacturer can be liable for damages for many different reasons. Eisai marketed and distributed a medication that posed a risk to those taking it and they failed to warn those people of the risks associated with it. Eisai was well aware that there was risk of developing debilitating cancers from the use of its drug.

If you or a loved one have been diagnosed with cancer following the use of weight-loss medication Belviq, the attorneys at the Neumann Law Group are here to help. You can speak with one of our qualified intake specialists at (800) 525-6386 or complete our online form. We have attorneys in Grand Rapids, Detroit, and Traverse City at the ready to take on pharmaceutical companies on your behalf. We can also help people who have been injured from defective medical devices, consumer products, or mass torts.